{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:52:01Z","timestamp":1791291121169,"version":"4.3.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"DOI":"10.1093\/neuonc\/nov019","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T05:34:01Z","timestamp":1423546441000},"page":"1007-1015","source":"Crossref","is-referenced-by-count":41,"title":["Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma"],"prefix":"10.1093","volume":"17","author":[{"given":"Ulrik","family":"Lassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier L.","family":"Chinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"McBain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Mau-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke Andr\u00e9e","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Krieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Habben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Lahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,9]]},"reference":[{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling - in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"Carmeliet","year":"2001","journal-title":"Nat Med"},{"issue":"(12)","key":"key\n\t\t\t\t20171010085642_NOV019C4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","article-title":"FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?","volume":"8","author":"Fischer","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"(4)","key":"key\n\t\t\t\t20171010085642_NOV019C5","first-page":"239","article-title":"PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance","volume":"6","author":"Escudero-Esparza","year":"2009","journal-title":"Cancer Genomics Proteomics"},{"issue":"(10)","key":"key\n\t\t\t\t20171010085642_NOV019C6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/hed.21335","article-title":"Expression of placenta growth factor: an independent factor for prediction of progression and prognosis of oral cancer","volume":"32","author":"Cheng","year":"2010","journal-title":"Head Neck"},{"issue":"(2)","key":"key\n\t\t\t\t20171010085642_NOV019C7","first-page":"537","article-title":"PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance","volume":"23","author":"Escudero-Esparza","year":"2010","journal-title":"Oncol Rep"},{"issue":"(9)","key":"key\n\t\t\t\t20171010085642_NOV019C8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3174\/ajnr.A2263","article-title":"Perfusion CT imaging of brain tumors: an overview","volume":"32","author":"Jain","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2008.0039","article-title":"Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities","volume":"6","author":"Wong","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"(28)","key":"key\n\t\t\t\t20171010085642_NOV019C10","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"issue":"(11)","key":"key\n\t\t\t\t20171010085642_NOV019C12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin\u00ae) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"issue":"(4)","key":"key\n\t\t\t\t20171010085642_NOV019C13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00109-013-1019-z","article-title":"Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme","volume":"91","author":"Soda","year":"2013","journal-title":"J Mol Med (Berl)"},{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C14","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-10-2687","article-title":"Placental growth factor upregulation is a host response to antiangiogenic therapy","volume":"17","author":"Bagley","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"(1)","key":"key\n\t\t\t\t20171010085642_NOV019C15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"issue":"(3)","key":"key\n\t\t\t\t20171010085642_NOV019C16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","article-title":"Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels","volume":"131","author":"Fischer","year":"2007","journal-title":"Cell"},{"issue":"(16)","key":"key\n\t\t\t\t20171010085642_NOV019C17","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1158\/0008-5472.CAN-09-4092","article-title":"Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation","volume":"70","author":"Coenegrachts","year":"2010","journal-title":"Cancer Res"},{"issue":"(9)","key":"key\n\t\t\t\t20171010085642_NOV019C18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.clinthera.2011.08.007","article-title":"Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects","volume":"33","author":"Martinsson-Niskanen","year":"2011","journal-title":"Clin Ther"},{"issue":"(4)","key":"key\n\t\t\t\t20171010085642_NOV019C19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/bjc.2011.609","article-title":"A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours","volume":"106","author":"Lassen","year":"2012","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20171010085642_NOV019C20","article-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"US Department of Health and Human Services","year":"2010"},{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"(11)","key":"key\n\t\t\t\t20171010085642_NOV019C22","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"(2)","key":"key\n\t\t\t\t20171010085642_NOV019C23","doi-asserted-by":"crossref","first-page":"W134","DOI":"10.2214\/AJR.09.3116","article-title":"Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses","volume":"194","author":"Ng","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"key\n\t\t\t\t20171010085642_NOV019C24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4137\/CMO.S8503","article-title":"Bevacizumab for the treatment of glioblastoma","volume":"7","author":"Gil-Gil","year":"2013","journal-title":"Clin Med Insights Oncol"},{"issue":"(12)","key":"key\n\t\t\t\t20171010085642_NOV019C25","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/bjc.2012.184","article-title":"Value of DCE-MRI and FDG-PET\/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases","volume":"106","author":"De Bruyne","year":"2012","journal-title":"Br J Cancer"},{"issue":"(10)","key":"key\n\t\t\t\t20171010085642_NOV019C26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","article-title":"Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence","volume":"70","author":"Norden","year":"2008","journal-title":"Neurology"},{"issue":"(12)","key":"key\n\t\t\t\t20171010085642_NOV019C27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1634\/theoncologist.2010-0105","article-title":"Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study","volume":"15","author":"Vredenburgh","year":"2010","journal-title":"Oncologist"},{"issue":"(3)","key":"key\n\t\t\t\t20171010085642_NOV019C28","first-page":"392","article-title":"Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma","volume":"16","author":"Tabouret","year":"2013","journal-title":"Neuro Oncol"},{"issue":"(1)","key":"key\n\t\t\t\t20171010085642_NOV019C29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1947601909356574","article-title":"Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates","volume":"1","author":"Loges","year":"2010","journal-title":"Genes Cancer"},{"issue":"(18)","key":"key\n\t\t\t\t20171010085642_NOV019C30","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"Willett","year":"2009","journal-title":"J Clin Oncol"},{"issue":"(5)","key":"key\n\t\t\t\t20171010085642_NOV019C31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer","volume":"24","author":"Wedam","year":"2006","journal-title":"J Clin Oncol"},{"issue":"(41)","key":"key\n\t\t\t\t20171010085642_NOV019C32","doi-asserted-by":"crossref","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","article-title":"Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR","volume":"269","author":"Park","year":"1994","journal-title":"J Biol Chem"},{"issue":"(3)","key":"key\n\t\t\t\t20171010085642_NOV019C33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cardiores.2004.12.002","article-title":"The biology of vascular endothelial growth factors","volume":"65","author":"Tammela","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"(9)","key":"key\n\t\t\t\t20171010085642_NOV019C34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"issue":"(Suppl)","key":"key\n\t\t\t\t20171010085642_NOV019C35","first-page":"118s","article-title":"A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET)","volume":"31","author":"Field","year":"2013","journal-title":"J Clin Oncol"},{"issue":"(1)","key":"key\n\t\t\t\t20171010085642_NOV019C36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cell.2010.01.033","article-title":"PlGF blockade does not inhibit angiogenesis during primary tumor growth","volume":"141","author":"Bais","year":"2010","journal-title":"Cell"},{"issue":"(1)","key":"key\n\t\t\t\t20171010085642_NOV019C37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cell.2010.02.039","article-title":"Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease","volume":"141","author":"Van de Veire","year":"2010","journal-title":"Cell"},{"issue":"(19)","key":"key\n\t\t\t\t20171010085642_NOV019C38","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2010.34.1636","article-title":"Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study","volume":"29","author":"de Groot","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/17\/7\/1007\/20890664\/nov019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T04:14:54Z","timestamp":1651205694000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article\/17\/7\/1007\/1297358\/Phase-1-doseescalation-study-of-the-antiplacental"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,9]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,2,9]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nov019","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,2,9]]}}}